Publications by authors named "Ruth Perets"

Claim this Profile
P
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.
Kevin J Harrington, Stephane Champiat, Joshua D Brody, Byoung Chul Cho, Emanuela Romano, Ruth Perets

Clin Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.
Loic Verlingue, Antoine Italiano, Hans Prenen, Eva Maria Guerra Alia, Diego Tosi, Ruth Perets

EBioMedicine· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies.
Ronnie Shapira-Frommer, Jiaxin Niu, Ruth Perets, Solange Peters, Geoffrey Shouse

Future Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors.
Ravit Geva, Maria Vieito, Jorge Ramon, Ruth Perets, Manuel Pedregal

Cancer Immunol Immunother· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.
Hans Prenen, Sanjeev Deva, Bhumsuk Keam, Colin R Lindsay, Iwona Lugowska, Ruth Perets

Clin Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233].
Dotan Moskovich, Adi Alfandari, Yael Finkelshtein, Avivit Weisz, Aviva Katzav, Ruth Perets

Cancer Lett· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors.
Victor Moreno, Ruth Perets, Tamar Peretz-Yablonski, Nele Fourneau, Suzette Girgis

Invest New Drugs· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
Toni K Choueiri, Harriet Kluger, Saby George, Scott S Tykodi, Timothy M Kuzel, Ruth Perets

J Immunother Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Lillian L Siu, Ding Wang, John Hilton, Ravit Geva, Drew Rasco, Ruth Perets

Clin Cancer Res· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAX8 in the Junction between Development and Tumorigenesis.
Reli Rachel Kakun, Zohar Melamed, Ruth Perets

Int J Mol Sci· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Lillian L Siu, Ding Wang, John Hilton, Ravit Geva, Drew Rasco, Ruth Perets

Clin Cancer Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Lillian L Siu, Ding Wang, John Hilton, Ravit Geva, Drew Rasco, Ruth Perets

Clin Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
Gerald S Falchook, Marc Peeters, Sylvie Rottey, Luc Y Dirix, Radka Obermannova, Ruth Perets

Invest New Drugs· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer.
Byoung Chul Cho, Kiyotaka Yoh, Ruth Perets, Adnan Nagrial, David R Spigel

Lung Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAX8 plays an essential antiapoptotic role in uterine serous papillary cancer.
Basem Fares, Liron Berger, Einav Bangiev-Girsh, Reli Rachel Kakun, Dima Ghannam-Shahbari, Ruth Perets

Oncogene· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutated p53 in HGSC-From a Common Mutation to a Target for Therapy.
Aya Saleh, Ruth Perets

Cancers (Basel)· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.
Dotan Moskovich, Adi Alfandari, Yael Finkelshtein, Avivit Weisz, Aviva Katzav, Ruth Perets

Cancer Lett· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?
Tarek Taha, Ari Reiss, Amnon Amit, Ruth Perets

BioDrugs· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients.
Alberto A Gabizon, Esther Tahover, Talia Golan, Ravit Geva, Ruth Perets

Invest New Drugs· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment.
Eleni Maniati, Chiara Berlato, Ganga Gopinathan, Owen Heath, Panoraia Kotantaki, Ruth Perets

Cell Rep· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
Hyun Cheol Chung, Willeke Ros, Jean-Pierre Delord, Ruth Perets, Antoine Italiano

J Clin Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study.
Ravit Geva, Juanita Lopez, Sarah Danson, Heikki Joensuu, Avivit Peer, Ruth Perets

Eur J Nucl Med Mol Imaging· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts.
Mark A Eckert, Fabian Coscia, Agnieszka Chryplewicz, Jae Won Chang, Kyle M Hernandez, Ruth Perets

Nature· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucocorticoids as an adjunct to oncologic treatment in solid malignancies - Not an innocent bystander.
Corinne Maurice-Dror, Ruth Perets, Gil Bar-Sela

Crit Rev Oncol Hematol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
Dima Ghannam-Shahbari, Eyal Jacob, Reli Rachel Kakun, Tanya Wasserman, Lina Korsensky, Ruth Perets

Oncogene· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis